Pre-Conference Workshops

Tuesday February 9, 2021 | 10am - 4.30 pm EST | 7am - pm PST

In Partnership With:

HW201203 CDx Engage logo update FINAL

In addition to the three main conference days at the 5th LBx for Precision Oncology Summit,
CDx Engage is hosting a day of pre-conference workshops in partnership with Guardant Health & Burning Rock.

Each workshop requires separate registration and will be 3 hours long. As with all CDx Engage events, these deep-dive workshops are free to attend with places subject to our partner’s final approval.

Register below for your selected workshops. If you would like to attend both, please complete both forms.

Hurry! Places are limited!

Burning-Rock-Dx

Overcoming Challenges of Running Clinical Trials in China & Implications for Global Trials

10am -1pm EST | 7am - 10am PST

The China commercial and regulatory environment has proven to be one of the most difficult regions in the world. We are seeing that the Chinese precision oncology market
is growing exponentially and is projected to reach $40B by 2030.

There is much confusion on best strategy and best practices of how to commercialize a precision oncology therapeutic, how to run clinical trials, and assay reimbursement as well
as legality. With significant challenges regarding access to the required data and results, reports from patients in China and Biosample export restrictions are extremely stringent.

Join leading experts at this workshop to discuss:

  • How to navigate the regulatory environment in China
  • What are the trends? What are the challenges and how can we adapt?
  • How does this fit with Global Trials?
  • How can we help with commercialization/reimbursement/Day 1 assay availability?
  • How can we help get HGRAC/NMPA approval for trials or biomarker work?
  • Data Sharing, HGRAC Approval, Changes to new CDx Indications
  • Clinical Biomarker work and how to get your studies approved
Guardant Health

Advancing LBx Clinical Utility & Global Commercialization

1.30pm - 4.30pm EST | 10.30am - 1.30pm PST

Liquid biopsies have attracted considerable attention as potential diagnostic, prognostic, predictive, and screening assays in oncology.

Clinical-translational studies are needed to establish the diagnostic accuracy and clinical utility of liquid biopsy biomarkers. Investigators must fully consider relevant pre-analytical variables, assay sensitivity, bioinformatics considerations as well as the clinical utility of rare event profiling in the context of the normal blood background.

This session will provide an outlook on the clinical disruption brought by LBx and the commercial strategies to impact patient care globally, from Biopharma and Translational Medical Centre perspectives.

Join leading experts at this workshop to discuss:

  • An LBx outlook: clinical trials and innovation needs
  • LBx utility in detection of disease progression
  • Global commercialization strategies for CDx

Burning Rock (AM) Workshop

Guardant Health (PM) Workshop

As with all CDx Engage events, these deep-dive workshops are free to attend with places subject to our partner’s final approval.